Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 6;24(9):585–591. doi: 10.1002/clc.4960240904

The 4G/5G promotor polymorphism of the plasminogen activator inhibitor‐1 gene and late lumen loss after coronary stent placement in smoking and nonsmoking patients

Jan R Ortlepp 1,✉, Rainer Hoffmann 2, Astrid Killian 3, Johannes Lauscher 4, Sabine Merkelbach‐Bruse 5, Peter Hanrath 6
PMCID: PMC6654891  PMID: 11558839

Abstract

Background: Instent restenosis remains a significant clinical problem. Identification of patients at risk for instent restenosis may allow selection of individualized appropriate therapeutic approaches. Genetic polymorphisms have been suggested to be associated with the risk of instent restenosis. Smoking is known to influence hemostatic parameters.

Hypothesis: This study investigated the influence of the 4G/5G promotor polymorphism of the plasminogen activator inhibitor type 1 (PAI‐1) gene on instent restenosis in smoking and nonsmoking patients.

Methods: in all, 300 consecutive patients (133 nonsmoking; 167 smoking) with elective coronary stent placement and 6‐month angiographic follow‐up were studied. Quantitative coronary angiography and genotyping with polymerase chain reaction analysis were performed in all patients.

Results: Nonsmoking PAI‐1 4G/4G carriers showed a significantly greater late lumen loss (n = 38; 0.54 ± 0.53 mm) compared with nonsmoking PAI‐14G/5G (n = 68; 0.38 ± 0.45 mm) or 5G/5G (n = 27; 0.19 ± 0.23 mm) carriers, analysis of variance (ANOVA) p<0.001. Smoking patients with the genotypes 4G/4G (n = 46; 0.53 ± 0.54 mm) and 4G/5G (n = 79; 0.37 ± 0.41 mm) had a late loss similar to that of nonsmoking patients. Smoking 5G/5G carriers had the highest late loss of all smoking patients (n = 42; 0.63 ± 0.50); ANOVA p < 0.05; nonsmoking 5G/5G vs. smoking 5G/5G p < 0.001.

Conclusion: The promotor polymorphism of the PAI‐1 gene has a significant influence on instent restenosis after coronary stent implantation. The 5G/5G genotype predisposes nonsmoking gene carriers to less late lumen loss, whereas in smoking gene carriers this genotype is associated with the greatest late lumen loss. This might be explained by an altered expression pattern of hemostatic parameters.

Keywords: restenosis, polymorphism, plasminogen activator inhibitor type 1, smoking, environmental‐genetic interaction

Full Text

The Full Text of this article is available as a PDF (634.4 KB).

References

  • 1. Fischman DL, Leon MD, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish RD, Colombo A, Brinker J, Moses J, Shaknovich A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S: A randomized comparison of coronary‐stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331, 496–501 [DOI] [PubMed] [Google Scholar]
  • 2. Serruys PW de Jaeger P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ van den Heuvel R Delcan J, Morel MA: A comparison of balloon‐expandable‐stent implantation with balloon angioplasty in patients with coronary heart disease. N Engl J Med 1994; 331: 489–495 [DOI] [PubMed] [Google Scholar]
  • 3. Mintz GS, Hoffmann R, Mehran R, Pichard AD, Kent KM, Satler LF, Popma JJ, Leon MB: In‐stent restenosis: The Washington Hospital Center experience. Am J Cardiol 1998; 81: 7E–13E [DOI] [PubMed] [Google Scholar]
  • 4. Kastrati A, Schömig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, Wehinger A, Hausleiter J, Walter H, Neuman FJ: Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997; 30: 1428–1436 [DOI] [PubMed] [Google Scholar]
  • 5. Bauters C, Hubert E, Prat A, Bougrimi K, Van Belle E, McFadden EP, Amouyel P, Lablanche JM, Bertrand M: Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol 1998; 31: 1291–1298 [DOI] [PubMed] [Google Scholar]
  • 6. Ribichini F, Steffenino G, Dellavalle A, Matullo G, Colajanni E, Camilla T, Vado A, Benetton G, Uslenghi E, Piazza A: Plasma activity and insertion/deletion polymorphims of angiotensin‐I‐converting enzyme: A major risk factor and a marker of risk for coronary stent restenosis. Circulation 1998; 97: 147–154 [DOI] [PubMed] [Google Scholar]
  • 7. Kastrati A, Schomig A, Seyfarth M, Koch W, Elezi S, Bottinger C, Mehilli J, Schomig K von Beckerath N: PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation 1999; 99: 1005–1010 [DOI] [PubMed] [Google Scholar]
  • 8. Strauss BH, Lau HK, Bowman KA, Sparkes J, Chrisholm RJ, Garvey B, Fenkell LL, Natarajan MK, Singh I, Teitel JM: Plasma urokinase antigen and plasminogen activator inhibitor‐1 antigen levels predict angiographic coronary restenosis. Circulation 1999; 100: 1616–1622 [DOI] [PubMed] [Google Scholar]
  • 9. Pepine CJ, Holmes DR: Coronary artery stents: ACC Expert Consensus Document. J Am Coll Cardiol 1996; 28: 782–794 [PubMed] [Google Scholar]
  • 10. Radke PW, Klues HG, Haager PK, Hoffmann R, Kastrau F, Reffelmann T, Janssens U vom Dahl J, Hanrath P: Mechanisms of acute lumen gain and recurrent restenosis after rotational atherectomy of diffuse instent restenosis: A quantitative angiographic and intravascular ultrasound study. J Am Coll Cardiol 1999, 34: 33–39 [DOI] [PubMed] [Google Scholar]
  • 11. Eriksson R Kallin B, Van'T Hooft FM, Bavenholm P, Hamsten A: Allele‐specific increase in basal transcription of the plasminogen‐activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851–1855 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Reidy MA, Irvin C, Lindner V: Migration of arterial wall cells: Expression of plasminogen activators and inhibitors in injured rat carotid arteries. Circ Res 1996; 78: 405‐414 [DOI] [PubMed] [Google Scholar]
  • 13. Hasenstab D, Forough R, Clowes AW: Plasminogen activator inhibitortype 1 and tissue inhibitor of metalloproteinases‐2 increases after arterial injury in rats. Circ Res 1997; 80: 490–496 [DOI] [PubMed] [Google Scholar]
  • 14. Sawa H, Lundgren C, Sobel BE, Fujii S: Increased intramural expression of plasminogen activator inhibitor type 1 after balloon injury: A potential progenitor of restenosis. J Am Coll Cardiol 1994; 24 lpar;7): 1742–1748 [DOI] [PubMed] [Google Scholar]
  • 15. Sandberg T, Casslen B, Gustavsson B, Benraad TJ: Human endothelial cell migration is stimulated by urokinase plasminogen activator:plasminogen activator inhibitor 1 complex released from endometrial stromal cells stimulated with transforming growth factor beta 1: Possible mechanism for paracrine stimulation of endometrial angiogenesis. Biol Reprod 1998; 59 lpar;4): 759–767 [DOI] [PubMed] [Google Scholar]
  • 16. Huber K, Jorg M, Probst P, Schuster E, Lang I, Kaindl F, Binder BR: A decrease in plasminogen activator inhibitor‐1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significant reduced risk for coronary restenosis. Thromb Haemost 1992; 67 lpar;2): 209–213 [PubMed] [Google Scholar]
  • 17. Gottsauner‐Wolf M, Sochor H, Hornykewycz S, Beckmann R, Lang I, Probst P, Binder BR, Huber K: Predictive value of PAI‐1 plasma activity and thallium perfusion imaging for restenosis after percutaneous transluminal angioplasty in clinically asymptomatic patients. Thromb Haemost 1999; 81 lpar;4): 522–526 [PubMed] [Google Scholar]
  • 18. Xiaoli M, Wenying H, Mingpeng S: Effects and mechanism of tissue‐type plasminogen activator and plasminogen activator inhibitor on vascular smooth muscle cell proliferation. Int J Cardiol 1998; 66 (suppl l):S57–65 [DOI] [PubMed] [Google Scholar]
  • 19. Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D, Gerard RD: Inhibitory role of plasminogen activator inhibitor‐1 in arterial wound healing and neointima formation: A gene targeting and gene transfer study in mice. Circulation 1997; 96: 3180–3191 [DOI] [PubMed] [Google Scholar]
  • 20. Carmeliet P, Moons L, Herbert JM, Crawley J, Lupu F, Lijnen R, Collen D: Urokinase but not tissue plasminogen activator mediates arterial neointimal formation in mice. Circ Res 1997; 81: 829–839 [DOI] [PubMed] [Google Scholar]
  • 21. Iwai N, Shimoike H, Nakamura Y, Tamaki, S , Kinoshita M: The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes. Atherosclerosis 1998; 136 lpar;1): 109–114 [DOI] [PubMed] [Google Scholar]
  • 22. Grancha S, Estelles A, Torno G, Falco C, Gilabert J, Espana F, Cano A, Segui R, Aznar J: Plasminogen activator inhibitor‐1 (PAI‐1) promotor 4G/5G genotype and increased PAI‐1 circulating levels in postmenopausal women with coronary artery disease. Thromb Haemost 1999; 81 lpar;4): 516–521 [PubMed] [Google Scholar]
  • 23. Ossei‐Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ: Plasminogen activator inhibitor‐1 promotor 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by angiography. Arterioscler Thromb Vase Biol 1997: 17 (l): 33–37 [DOI] [PubMed] [Google Scholar]
  • 24. Balasa VV, Gruppo RA, Glueck CJ, Stroop D, Becker A, Pillow A, Wang P: The relationship of mutations in the MTHFR, prothrombin, and PAI‐1 genes to plasma levels of homocysteine, prothrombin, and PAI‐1 in children and adults. Thromb Haemost 1999; 81 (5): 739–744 [PubMed] [Google Scholar]
  • 25. Feng DL, Lindpaintner K, Larson MG O'Donnel CJ, Lipinska I, Sutherland PA, Levy D Tofler GH: The contribution of genetic (4G/5G polymorphism) and environmental factors to plasminogen activator inhibitor‐1 antigen levels: The Framingham Offspring Study. J Am Coll Cardiol 1999; 33 (2 suppl) (): 312A [Google Scholar]
  • 26. Eliasson M, Asplund K, Evrin PE, Lundblad D: Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin. The Northern Sweden MONICA study. Atherosclerosis 1995; 113: 41–53 [DOI] [PubMed] [Google Scholar]
  • 27. Hughes K, Choo M, Kuperan P, Ong CN, Aw TC: Cardiovascular risk factors in relation to cigarette smoking: A population‐based survey among Asians in Singapore. Atherosclerosis 1998: 137: 253–258 [DOI] [PubMed] [Google Scholar]
  • 28. Simpson AJ, Gray RS, Moore NR, Booth NA: The effects of chronic smoking on the fibrinolytic potential and platelets. Br J Haematol 1997; 97 (1): 208–213 [DOI] [PubMed] [Google Scholar]
  • 29. Hashimoto Y, Kobayashi A, Yamazaki N, Takada Y, Takada A: Relationship between smoking and fibrinolytic system with special reference to tPA and PA inhibitor. Thromb Res 1988; 51 (3): 303–311 [DOI] [PubMed] [Google Scholar]
  • 30. Haire WD, Goldsmith JC, Rasmussen J: Abnormal fibrinolysis in healthy male cigarette smokers: Role of plasminogen activator inhibitors. Am J Hematol 1989: 31 (1): 36–40 [DOI] [PubMed] [Google Scholar]
  • 31. Editorial: Freely association. Nature Genetics 1999: 22: 1–2 10319845 [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES